Clinical Trial Update: A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation [Phase 2]

View source ↗

Summary

A Phase 2 study of XPro1595 in early Alzheimer's disease with biomarkers of inflammation has completed. The trial was sponsored by Inmune Bio, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• XPro1595 (XPro1595)

Snippet

Sponsor: Inmune Bio, Inc. | Conditions: Alzheimer Disease, Dementia | Phase 2 | Status: COMPLETED